TargetMol
Calycosin-7-O-β-D-glucoside (calycosin-7-O-beta-D-glucopyranoside) possesses a protective effect on rat hepatocytes, an inhibitory effect on COX-2 activity. Calycosin 7-O-β-D-glucoside has antimicrobial activity. Calycosin 7-O-β-D-glucoside is a promising anti-HIV agent. It shows scavenging activity to DPPH radicals and superoxide anion. Calycosin 7-O-β-D-glucopyranoside possesses an alleviating effect on osteoarthritis and can increase the fluidity of brain cell membrane in […]
More Information
Supplier Page
TargetMol
Calycosin-7-O-β-D-glucoside (calycosin-7-O-beta-D-glucopyranoside) possesses a protective effect on rat hepatocytes, an inhibitory effect on COX-2 activity. Calycosin 7-O-β-D-glucoside has antimicrobial activity. Calycosin 7-O-β-D-glucoside is a promising anti-HIV agent. It shows scavenging activity to DPPH radicals and superoxide anion. Calycosin 7-O-β-D-glucopyranoside possesses an alleviating effect on osteoarthritis and can increase the fluidity of brain cell membrane in […]
More Information
Supplier Page
Rapastinel
1 mg
| Purity Not Available
TargetMol
ML281
2 mg
| 99.77%
TargetMol
TargetMol
TargetMol
CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, 5 and 1, respectively.
More Information
Supplier Page
TargetMol
CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, 5 and 1, respectively.
More Information
Supplier Page
TargetMol
CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, 5 and 1, respectively.
More Information
Supplier Page
TargetMol
TargetMol
